Back

γδ T cells modulate anti-tumor immunity in small cell lung cancer

Ng, J.; You, Y.; Zhang, T. Z.; Hess, J. B.; Best, S. A.; Caneborg, A.; Schmiel, M.; Godfrey, D. I.; Wu, Y.; Tothill, R. W.; Antilla, C. J. A.; Baldwin, T. M.; Naik, S. H.; Amman-Zalcenstein, D.; Kersbergen, A. J.; Leong, T. L.; George, J.; Ritchie, M. E.; Gherardin, N. A.; Koay, H.-F.; Hickey, P. F.; Steinfort, D.; Sutherland, K. D.

2025-09-04 cancer biology
10.1101/2025.09.04.674147 bioRxiv
Show abstract

Small cell lung cancer (SCLC) is a highly aggressive neoplasm with limited sensitivity to anti-PD-(L)1 blockade, likely due to the epigenetic silencing of MHC-I. Elucidating MHC-I-independent immune recognition mechanisms is therefore crucial for enhancing treatment responses and improving clinical outcomes in a greater number of patients. Leveraging single cell approaches, we discovered {gamma}{delta} T cell infiltration in biospecimens from patients with SCLC. Despite PD-1 expression, {gamma}{delta} T cells maintained a cytotoxic transcriptional profile, suggestive of an anti-tumor role. Indeed, high {gamma}{delta} T cell infiltration predicted improved response to anti-PD-L1 immunotherapy in patients with SCLC. Moreover, using pre-clinical models, we demonstrated that {gamma}{delta} T cells are effective at tarlatamab (DLL3-CD3 BiTE) redirected SCLC killing and that zoledronate, an FDA-approved compound, can sensitize SCLC cells to {gamma}{delta} T cell-mediated killing. Thus, our findings suggest that engaged {gamma}{delta} T cells are potentially valuable targets for SCLC therapy.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.